Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
General Rheumatology
•
Infectious Disease
•
Vaccines
•
Immunosuppression
•
Measles
In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?
Related Questions
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Do you find HZV titers useful in diagnosing shingles sine herpete?
How often do you see bony erosions in patients with Lyme arthritis?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
Is it better to give dose 2 of the mRNA 2024-2025 Covid-19 vaccine at month 2 or month 6 after dose 1 in moderately immunocompromised patients?
What is the interpretation of an IGRA with positive TB wells and negative nil and negative mitogen wells?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
